Bussiness Ideas

SynapBiome Therapeutics is a preclinical biotechnology startup focused on developing a novel platform to decode gut microbiome–derived small RNA signals as early biomarkers and therapeutic targets for Parkinson’s disease. Parkinson’s disease is typically diagnosed after significant and irreversible neuronal damage has already occurred, limiting the effectiveness of current treatments. Although gut microbiome alterations have been consistently observed in Parkinson’s patients, existing approaches are largely descriptive and do not identify the molecular mechanisms linking gut dysbiosis to neurodegeneration. Our innovation lies in shifting the focus from microbial composition to functional molecular signaling. We investigate regulatory small RNAs produced by gut microbes that may influence neuronal pathways, inflammation, oxidative stress, and protein aggregation associated with disease progression. The platform integrates clinically annotated microbiome profiling, targeted small RNA sequencing, and functional validation in neuronal systems to establish mechanistic relevance. This approach enables the identification of early-stage biomarkers and upstream disease-modifying targets, creating opportunities for both diagnostic and therapeutic development. With strong intellectual property potential and scalability, the platform can be extended beyond Parkinson’s disease to other neurodegenerative and neuroinflammatory disorders. SynapBiome aims to bridge fundamental gut–brain biology with translational innovation, contributing to early detection and precision intervention strategies in neurodegenerative diseases.

Show More

Startup Teams

• 1 Prafulla Chandra Tiwari (Founder)
• 2 Pravesh Chandra Tiwari (Founder)

Incubation Details

Not Incubated